Philip R Krause

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. doi request reprint Goals of stability evaluation throughout the vaccine life cycle
    Philip R Krause
    FDA CBER OVRR DVP, Bethesda, MD 20892 4555, USA
    Biologicals 37:369-78; discussion 421-3. 2009
  2. doi request reprint Characterization of Herpes Simplex Virus 2 Primary MicroRNA Transcript Regulation
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA
    J Virol 89:4837-48. 2015
  3. doi request reprint Priorities for CMV vaccine development
    Philip R Krause
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, United States Electronic address
    Vaccine 32:4-10. 2013
  4. doi request reprint Universal virus detection by degenerate-oligonucleotide primed polymerase chain reaction of purified viral nucleic acids
    Santosh Nanda
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda 20892 4555, United States
    J Virol Methods 152:18-24. 2008
  5. pmc Herpes simplex virus 2 microRNA miR-H6 is a novel latency-associated transcript-associated microRNA, but reduction of its expression does not influence the establishment of viral latency or the recurrence phenotype
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 85:4501-9. 2011
  6. pmc Latency-associated transcript (LAT) exon 1 controls herpes simplex virus species-specific phenotypes: reactivation in the guinea pig genital model and neuron subtype-specific latent expression of LAT
    Andrea S Bertke
    FDA CBER, Bethesda, Maryland 20892 4555, USA
    J Virol 83:10007-15. 2009
  7. pmc Novel less-abundant viral microRNAs encoded by herpes simplex virus 2 latency-associated transcript and their roles in regulating ICP34.5 and ICP0 mRNAs
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892 4555, USA
    J Virol 83:1433-42. 2009
  8. doi request reprint Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program
    Daniel A Salmon
    National Vaccine Program Office, Office of Public Health and Science, Department of Health and Human Services, 200 Independence Ave, Washington, DC 20201, USA
    Pediatrics 127:S78-86. 2011
  9. pmc Use of a universal virus detection assay to identify human metapneumovirus in a hematopoietic stem cell transplant recipient with pneumonia of unknown origin
    Christine Uhlenhaut
    Division of Viral Products, Center for Biologics, Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892 4555, USA
    J Clin Virol 44:337-9. 2009
  10. pmc Spread of herpes simplex virus to the spinal cord is independent of spread to dorsal root ganglia
    Masahiro Ohashi
    FDA CBER, HFM 457, 29 Lincoln Drive, Bethesda, MD 20892 4555, USA
    J Virol 85:3030-2. 2011

Collaborators

Detail Information

Publications16

  1. doi request reprint Goals of stability evaluation throughout the vaccine life cycle
    Philip R Krause
    FDA CBER OVRR DVP, Bethesda, MD 20892 4555, USA
    Biologicals 37:369-78; discussion 421-3. 2009
    ..At each phase in the product life cycle, it is important to consider the goals of stability evaluation and to perform appropriate statistical analyses in order to assure and reach appropriate conclusions about product quality...
  2. doi request reprint Characterization of Herpes Simplex Virus 2 Primary MicroRNA Transcript Regulation
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA
    J Virol 89:4837-48. 2015
    ..The ability of ICP4 to suppress ICP34.5-targeting miRNAs and to activate lytic viral genes suggests that ICP4 could play a key role in the switch between latency and reactivation...
  3. doi request reprint Priorities for CMV vaccine development
    Philip R Krause
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, United States Electronic address
    Vaccine 32:4-10. 2013
    ....
  4. doi request reprint Universal virus detection by degenerate-oligonucleotide primed polymerase chain reaction of purified viral nucleic acids
    Santosh Nanda
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda 20892 4555, United States
    J Virol Methods 152:18-24. 2008
    ..This type of approach has potential utility in solving virus detection and discovery problems where other methods have failed...
  5. pmc Herpes simplex virus 2 microRNA miR-H6 is a novel latency-associated transcript-associated microRNA, but reduction of its expression does not influence the establishment of viral latency or the recurrence phenotype
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 85:4501-9. 2011
    ..We hypothesize that viral miRNAs associated with LAT expression are likely to work collectively, contributing to the phenotype attributed to the LAT...
  6. pmc Latency-associated transcript (LAT) exon 1 controls herpes simplex virus species-specific phenotypes: reactivation in the guinea pig genital model and neuron subtype-specific latent expression of LAT
    Andrea S Bertke
    FDA CBER, Bethesda, Maryland 20892 4555, USA
    J Virol 83:10007-15. 2009
    ....
  7. pmc Novel less-abundant viral microRNAs encoded by herpes simplex virus 2 latency-associated transcript and their roles in regulating ICP34.5 and ICP0 mRNAs
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892 4555, USA
    J Virol 83:1433-42. 2009
    ..All these data suggest that LAT sequences likely contribute to HSV latency and reactivation through tight control of these LAT-encoded miRNAs and their viral targets...
  8. doi request reprint Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program
    Daniel A Salmon
    National Vaccine Program Office, Office of Public Health and Science, Department of Health and Human Services, 200 Independence Ave, Washington, DC 20201, USA
    Pediatrics 127:S78-86. 2011
    ..These efforts improved monitoring of 2009 H1N1 vaccine safety, hold promise for enhancing future national monitoring of vaccine safety, and may ultimately help improve public confidence in vaccines...
  9. pmc Use of a universal virus detection assay to identify human metapneumovirus in a hematopoietic stem cell transplant recipient with pneumonia of unknown origin
    Christine Uhlenhaut
    Division of Viral Products, Center for Biologics, Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892 4555, USA
    J Clin Virol 44:337-9. 2009
    ..We present a case report of an immunocompromised patient suffering from pneumonia, for which the causative agent was not identified by routine methods...
  10. pmc Spread of herpes simplex virus to the spinal cord is independent of spread to dorsal root ganglia
    Masahiro Ohashi
    FDA CBER, HFM 457, 29 Lincoln Drive, Bethesda, MD 20892 4555, USA
    J Virol 85:3030-2. 2011
    ....
  11. pmc Discovery of a bovine enterovirus in alpaca
    Shasta D McClenahan
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    PLoS ONE 8:e68777. 2013
    ..Although this virus replicated in MDBK cells, existing standard culture and molecular methods could not identify it. In this case, a highly sensitive generic PCR-based pathogen-detection method was used to identify this pathogen. ..
  12. pmc Herpes simplex virus 2 expresses a novel form of ICP34.5, a major viral neurovirulence factor, through regulated alternative splicing
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    J Virol 87:5820-30. 2013
    ..5 splicing and promotion of ICP34.5β expression. Our results suggest that the expression of ICP34.5α and ICP34.5β is tightly regulated in HSV-2 and likely contributes to viral pathogenesis...
  13. doi request reprint Optimization of virus detection in cells using massively parallel sequencing
    Shasta D McClenahan
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Biologicals 42:34-41. 2014
    ....
  14. doi request reprint Evaluation of cells and biological reagents for adventitious agents using degenerate primer PCR and massively parallel sequencing
    Shasta D McClenahan
    Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
    Vaccine 32:7115-21. 2014
    ..The present study helps to illustrate the potential for MPS-based strategies in evaluating the presence of viral nucleic acids in various sample types, including cell culture substrates and vaccines. ..
  15. doi request reprint Molecular and infectivity studies of porcine circovirus in vaccines
    Shasta D McClenahan
    Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA CBER, Bethesda, MD 20892 4555, United States
    Vaccine 29:4745-53. 2011
    ..In these vaccines, molecular characterization of PCV nucleic acids was useful for predicting the results of cell culture assays...
  16. pmc An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 105:10931-6. 2008
    ..5, a key viral neurovirulence factor. We hypothesize that miR-I may modulate the outcome of viral infection in the peripheral nervous system by functioning as a molecular switch for ICP34.5 expression...